Evidence-informed pharmacology review updated 10 November 2026. Educational material, not a substitute for institutional protocols or individual clinical care.
Overview
Parasympathomimetics reproduce selected effects of acetylcholine at muscarinic receptors or increase endogenous acetylcholine by acetylcholinesterase (AChE) inhibition. Because AChE inhibition also increases transmission at nicotinic neuromuscular junctions and autonomic ganglia, indirect cholinomimetics are broader than purely parasympathetic agonists [1].
Mechanisms and correct classification
- Direct muscarinic agonists: bethanechol primarily stimulates muscarinic receptors in bladder/GI smooth muscle; pilocarpine acts on muscarinic receptors in salivary glands and the eye; cevimeline is used for selected dry-mouth syndromes.
- Carbachol: stimulates both muscarinic and nicotinic receptors and has selected ophthalmic uses.
- Reversible AChE inhibitors: neostigmine, pyridostigmine and physostigmine preserve ACh in synapses. Donepezil, rivastigmine and galantamine have central cholinergic actions in Alzheimer disease.
- Irreversible AChE inhibitors: organophosphates inhibit AChE and are predominantly toxicants, not routine parasympathomimetic therapies [1].
Important corrections to former classification
Tiotropium and tropicamide are antimuscarinic antagonists, not muscarinic agonists. Hexamethonium blocks neuronal nicotinic receptors in autonomic ganglia and is not a cholinergic agonist. D-tubocurarine is a neuromuscular nicotinic antagonist, not an agonist. Succinylcholine is a depolarizing neuromuscular blocker, not an ordinary parasympathomimetic. Muscarinic activation typically causes miosis and bronchoconstriction, not mydriasis and bronchodilation [1].
Clinical uses
Bethanechol has selected uses for nonobstructive urinary retention but is not routine therapy for all postoperative ileus. Pilocarpine/cevimeline can relieve xerostomia in eligible patients. Pyridostigmine provides symptomatic treatment in myasthenia gravis. Neostigmine reverses appropriate shallow nondepolarizing neuromuscular blockade, usually with an antimuscarinic to limit bradycardia/secretions; quantitative monitoring determines suitability. Central AChE inhibitors provide modest symptomatic cognitive benefit for selected dementia patients [1,2].
Pharmacokinetics and adverse effects
Quaternary compounds such as neostigmine and pyridostigmine have limited blood–brain barrier penetration, while tertiary physostigmine enters the CNS. Excess cholinergic activity may cause sweating, lacrimation, salivation, diarrhea, abdominal cramps, bradycardia, bronchospasm, urinary urgency and weakness. Cholinergic crisis due to excess AChE inhibition can mimic worsening neuromuscular disease, requiring urgent specialist assessment [1].
Contraindications and antidotal care
Avoid stimulating gastrointestinal or urinary smooth muscle when mechanical obstruction is present. Severe asthma, bradyarrhythmia and significant cardiac instability require individualized risk assessment. Organophosphate poisoning requires prompt decontamination when appropriate, supportive airway care and atropine for muscarinic features with an oxime such as pralidoxime when indicated; this differs from ordinary therapeutic cholinomimetic use [1].
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- American Society of Anesthesiologists. 2023 practice guidelines for monitoring and antagonism of neuromuscular blockade. Anesthesiology. 2023;138:13–41. doi:10.1097/ALN.0000000000004379. Available from: https://doi.org/10.1097/ALN.0000000000004379
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.